(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 50.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Ascendis Pharma A's revenue in 2026 is $751,801,162.On average, 17 Wall Street analysts forecast ASND's revenue for 2026 to be $81,566,038,260, with the lowest ASND revenue forecast at $67,085,775,288, and the highest ASND revenue forecast at $97,329,362,508. On average, 15 Wall Street analysts forecast ASND's revenue for 2027 to be $117,247,361,364, with the lowest ASND revenue forecast at $86,881,577,832, and the highest ASND revenue forecast at $151,951,113,972.
In 2028, ASND is forecast to generate $157,816,536,948 in revenue, with the lowest revenue forecast at $125,801,103,204 and the highest revenue forecast at $185,799,492,396.